Blue Earth Diagnostics, a subsidiary of Bracco Imaging, is a recognized leader in the
development and commercialization of novel PET radiopharmaceuticals to inform
clinical management for cancer patients. Its portfolio includes a commercial
product for recurrent prostate cancer and a robust pipeline of investigational
agents. For more information, visit: www.blueearthdiagnostics.com.